Cumberland Pharmaceuticals (CPIX) Interest & Investment Income (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) reported Interest & Investment Income of $78031.0 for Q1 2026, down 37.93% on a YoY basis from $125709.0 in Q1 2025, and down 15.15% sequentially from $91967.0 in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Interest & Investment Income (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 17 years of Interest & Investment Income data on file, last reported at $78031.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 37.93% year-over-year to $78031.0; the trailing twelve-month figure through Mar 2026 stood at $429070.0 (up 18.07% YoY), and the FY2025 full-year result was $476748.0, up 42.55% from the prior year.
- Interest & Investment Income eased to $78031.0 in Q1 2026, from $91967.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $131583.0 in Q3 2025 to a low of $15066.0 in Q2 2022.
- A 5-year average of $74969.5 and a median of $78031.0 in 2026 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income surged 585.1% in 2022 and tumbled 37.93% in 2026, its largest moves.
- Tracing CPIX's Interest & Investment Income over 5 years: stood at $45696.0 in 2022, then jumped by 77.26% to $81000.0 in 2023, then soared by 31.69% to $106667.0 in 2024, then dropped by 13.78% to $91967.0 in 2025, then decreased by 15.15% to $78031.0 in 2026.
- Business Quant data shows CPIX's Interest & Investment Income at $78031.0 in Q1 2026, $91967.0 in Q4 2025, and $131583.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Cumberland Pharmaceuticals | 106.37 Mn | 95.36 Mn | 7.20 Mn | 78,031.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78,031.00 |
| Dec 31, 2025 | 91,967.00 |
| Sep 30, 2025 | 131,583.00 |
| Jun 30, 2025 | 127,489.00 |
| Mar 31, 2025 | 125,709.00 |
| Dec 31, 2024 | 106,667.00 |
| Sep 30, 2024 | 69,190.00 |
| Jun 30, 2024 | 61,841.00 |
| Mar 31, 2024 | 96,746.00 |
| Dec 31, 2023 | 81,000.00 |
| Sep 30, 2023 | 98,603.00 |
| Jun 30, 2023 | 57,061.00 |
| Mar 31, 2023 | 50,190.00 |
| Dec 31, 2022 | 45,696.00 |
| Sep 30, 2022 | 21,602.00 |
| Jun 30, 2022 | 15,066.00 |
| Mar 31, 2022 | 16,041.00 |
| Dec 31, 2021 | 6,670.00 |
| Sep 30, 2021 | 7,394.00 |
| Jun 30, 2021 | 6,591.00 |